Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Researchers move closer to matching patients with GLP-1 drug that works best for them
05:59pm, Wednesday, 19'th Nov 2025
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amo
SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development
04:30pm, Wednesday, 19'th Nov 2025
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-bind
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
06:37pm, Monday, 17'th Nov 2025
Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON , Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leadi
Novo Nordisk: Modeling A GLP-1 Giant In Retreat And Recovery
04:25pm, Monday, 17'th Nov 2025
Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening semaglu
Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians
09:00am, Friday, 14'th Nov 2025
Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
02:00pm, Wednesday, 12'th Nov 2025
GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds.
GLP-1 prices are dropping: Who exactly will benefit?
10:25am, Tuesday, 11'th Nov 2025
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commerci
New Research from RGA: GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20 Years
09:00am, Tuesday, 11'th Nov 2025
ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global life and health reinsurer, published new in-depth research quantifying the mortality and morbidity
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
04:25am, Tuesday, 11'th Nov 2025
Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
11:31am, Monday, 10'th Nov 2025
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
01:58pm, Sunday, 09'th Nov 2025
Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer's drug, Kisunla, has blockbuster potential, and if efforts at early de
Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share
09:15am, Saturday, 08'th Nov 2025
LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former's triple digits GLP-1 revenue growth on a YoY basis. This is on top of LLY
Why Omada Health is finally prescribing Ozempic as TrumpRx slashes GLP-1 weight-loss drug costs
12:47pm, Friday, 07'th Nov 2025
Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
11:49am, Friday, 07'th Nov 2025
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but
Global Partners LP Common Units (GLP) Q3 2025 Earnings Call Transcript
11:16am, Friday, 07'th Nov 2025
Global Partners LP Common Units ( GLP ) Q3 2025 Earnings Call November 7, 2025 10:00 AM EST Company Participants Sean Geary - Chief Legal Officer & Secretary Eric Slifka - President, CEO & Vice Chairm
